International Journal of Hematology

, Volume 92, Issue 1, pp 25–32

Current treatment strategy and new agents in mantle cell lymphoma

Progress in Hematology Targeted treatment and new agents in malignant lymphoma

DOI: 10.1007/s12185-010-0607-8

Cite this article as:
Ogura, M. Int J Hematol (2010) 92: 25. doi:10.1007/s12185-010-0607-8


Mantle cell lymphoma (MCL) is a well-recognized lymphoma subtype that accounts for about 5% of all patients with non-Hodgkin lymphoma. The clinical course of MCL ranges from an indolent disease to a rapidly progressive malignancy, with a poor prognosis and a median overall survival (OS) of about 3–5 years reported in earlier data sets. Knowledge of its biology has increased in the last few years. Unfortunately, this progress has not yet brought any major improvements in therapeutic approaches, which still remain highly unsatisfactory. Recent improvement has been achieved by the successful introduction of monoclonal antibodies and dose-intensified approaches including autologous stem cell transplantation strategies. However, with the exception of allogeneic hematopoietic stem cell transplantation, current treatment approaches are non-curative, and the corresponding survival curves are characterized by a delayed but continuous decline and a median survival of 4–6 years. In recent years, new insights into the biology of MCL have been obtained which have provided the rationale for the development of novel therapeutic strategies. Emerging new drugs such as bendamustine, proteasome inhibitors, antibodies, mTOR inhibitors, and immunomodulatory drugs and others are based on the dysregulated control of cell cycle machinery and impaired apoptotic pathways. The efficacy of these agents as monotherapy was demonstrated to be comparable to conventional chemotherapy in relapsed MCL, and combination strategies are currently being investigated in clinical trials.


Mantle cell lymphoma Current treatment strategy Promising new agents 

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  1. 1.Department of Hematology and OncologyNagoya Daini Red Cross HospitalNagoyaJapan

Personalised recommendations